Long-Term Assets: The sum of all assets classified as non-current.
ARS Pharmaceuticals, Inc. (SPRY) had Long-Term Assets of $33.94M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$32.50M |
|
$-51.15M |
|
$8.19M |
|
$24.31M |
|
$85.69M |
|
$-53.19M |
|
$2.04M |
|
$-51.15M |
|
$-51.15M |
|
$-51.15M |
|
$-51.15M |
|
$-51.15M |
|
$-51.15M |
|
$-53.19M |
|
$-53.89M |
|
98.81M |
|
98.81M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$338.86M |
|
$1.21M |
|
|
Long-Term Assets |
$33.94M |
$372.80M |
|
$50.88M |
|
$168.27M |
|
$174.27M |
|
$225.15M |
|
$147.66M |
|
$132.93M |
|
$147.66M |
|
98.84M |
|
| Cash Flow Statement Financials | |
$-127.38M |
|
$32.65M |
|
$103.47M |
|
$50.82M |
|
$59.56M |
|
$8.74M |
|
$16.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.66 |
|
-- |
|
-- |
|
0.53 |
|
1.14 |
|
74.80% |
|
-163.66% |
|
-163.66% |
|
-- |
|
-157.38% |
|
-157.38% |
|
$-127.72M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
1.05 |
|
0.89 |
|
100.94 |
|
-34.64% |
|
-38.48% |
|
-13.72% |
|
-16.19% |
|
$1.49 |
|
$-1.29 |
|
$-1.29 |
|